Home

What is the ISCHEMIA Study? 

  • An NHLBI-funded international comparative effectiveness study to determine the best way to treat chronic coronary disease.
  • Patients with moderate or severe ischemia, with or without stress imaging, were eligible for participation.

What is the ISCHEMIA-CKD Study? 

  • An international comparative effectiveness study to determine the best way to manage chronic coronary disease in patients with advanced chronic kidney disease (eGFR <30 or on dialysis).
  • Patients with advanced CKD with moderate to severe ischemia on stress testing were randomized to this Study.  

What is ISCHEMIA-EXTEND?

  • ISCHEMIA-EXTEND is the long-term follow-up of randomized, surviving participants in the ISCHEMIA and ISCHEMIA-CKD trials.
  • ISCHEMIA-EXTEND assesses whether an initial invasive strategy—cardiac catheterization and revascularization when feasible plus optimal medical therapy (OMT)—reduces long-term all-cause mortality as compared with an initial conservative strategy of OMT for chronic coronary disease patients with moderate or severe ischemia over an extended 5 year period of follow-up.

Why is the ISCHEMIA Study Important?

  • Chronic coronary disease is the leading cause of death and disability worldwide and affects an estimated 18,200,000 Americans, resulting in about 541,000 deaths in the United States annually. Globally, 8.9 million deaths are caused by IHD each year. Medical therapy (medication and lifestyle changes) should always be used to treat IHD. The trial showed that heart procedures added to taking medicines and making lifestyle changes did not reduce the overall rate of cardiovascular death and heart attack compared with medicines and lifestyle changes alone. However, for people with chest pain symptoms, heart procedures improved symptoms better than medicines and lifestyle changes alone. The more chest pain to begin with, the more symptoms improved after getting a stent or bypass surgery.
  • For ISCHEMIA Study Results, please click here.

Why is ISCHEMIA-EXTEND Important?

  • The ISCHEMIA and ISCHEMIA-CKD trials did not demonstrate a reduction in their primary endpoints with an initial invasive strategy. All-cause mortality was similar over 5 years. There was an early excess of peri-procedural MI and a late reduction in spontaneous MI in both trials. Prior evidence demonstrates that spontaneous MI has a larger impact on subsequent death than most peri-procedural MI’s. Therefore, it is imperative to assess long-term all-cause mortality to provide patients and clinicians with robust evidence regarding survival following the two initial management strategies over the long-term (~10 years).
  • Understanding the impact of nonfatal events on subsequent mortality among patients with chronic coronary disease will influence clinical practice and the design of cardiovascular clinical trials for years to come. With the ever-increasing sensitivity of biomarker assays for MI, it is of paramount importance to understand the relationship between MI and subsequent death.

Total Number of Participants in ISCHEMIA-EXTEND:

  • Over 5,000 participants worldwide entered ISCHEMIA-EXTEND when this follow-up study began. Click here to see the participants by country.

Upcoming ISCHEMIA Presentations

  • There are no upcoming presentations at this time. Please continue to check back for updates!

Recent ISCHEMIA Presentations from ACC.2022

  • Relationship of Health Status to ISCHEMIA and Coronary Anatomy in the ISCHEMIA Trial (Poster presented by Dr. Lawrence M. Phillips) Link

For more Presentations, please CLICK HERE.

Recent ISCHEMIA Publications

  • Bangalore S, Spertus JA, Stevens SR, Jones PG, Mancini GBJ, Leipsic J, Reynolds HR, Budoff MJ, Hague CJ, Min JK, Boden WE, O’Brien SM, Harrington RA, Berger JS, Senior R, Peteiro JPandit N, Bershtein L, de Belder MA, Szwed H, Doerr R, Monti L, Alfakih K, Hochman JS, Maron DJ on behalf of the ISCHEMIA Research Group. Outcomes With Intermediate Left Main Disease: Analysis From the ISCHEMIA Trial. Circulation: Cardiovascular Interventions. 2022;15:e010925. Link
  • Mark DB, Spertus JA, Bigelow R, Anderson S, Daniels MR, Anstrom KJ, Baloch KN, Cohen DJ, Held C, Goodman SG, Bangalore S, Cyr D, Reynolds HR, Alexander KP, Rosenberg Y, Stone GW, Maron DJ on behalf of the ISCHEMIA Research Group. Comprehensive Quality of Life Outcomes with Invasive versus Conservative Management of Chronic Coronary Disease in ISCHEMIA. AHA Journals. Mar 9 2022 Link

  • Sidhu MS, Alexander KP, Huang Z, O'Brien SM, Chaitman BR, Stone GW, Newman JD, Boden WE, Maggioni AP, Steg PG, Ferguson TB, Demkow M, Peteiro J, Wander GS, Phaneuf DC, De Belder MA, Doerr R, Alexanderson-Rosas E, Polanczyk CA, Henriksen PA, Conway DSG, Miro V, Sharir T, Lopes RD, Min JK, Berman DS, Rockhold FW, Balter S, Borrego D, Rosenberg YD, Bangalore S, Reynolds HR, Hochman JS, Maron DJ. Causes of Cardiovascular and Non-Cardiovascular Death in the ISCHEMIA Trial. American Heart Journal. 2022. Link

  • Bainey KR, Fleg JL, Hochman JS, Kunichoff DF, Anthopolos R, Chernyavskiy AM, Demkow M, Lopez-Quijano JM, Escobedo J, Keong Poh K, Ramos RB, Lima EG, Schuchlenz H, Ali ZA, Stone GW, Maron DJ, O'Brien SM, Spertus JA, Bangalore S. Predictors of outcome in the ISCHEMIA-CKD trial: Anatomy versus ischemia. American Heart Journal. 2022. 243:187-200. Link

  • Newman JD, Anthopolos R, Mancini GBJ, Bangalore Sripal, Reynolds HR, Kunichoff DF, Senior R, Peteiro Jesus, Bhargava B, Garg P,  Escobedo J, Doerr R, Mazurek T, Gonzalez-Juanatey J, Gajos G, Briguori C, Cheng H, Vertes A, Mahajan S, Guzman LA, Matyas K, Maggioni AP, Stone GW, Berger JS, Rosenberg YD, Boden WE, Chaitman BR, Fleg JL, Hochman JS, Maron DJ. Outcomes of Participants with Diabetes in the ISCHEMIA Trials. AHA Journals. Sep 15 2021 Link

For more Publications, please CLICK HERE.